Kymera Therapeutics (KYMR) EBITDA (2019 - 2026)
Kymera Therapeutics (KYMR) reported EBITDA of -$75.2 million for Q1 2026, down 17.26% year-over-year from -$90.9 million in Q1 2025, and up 13.21% quarter-over-quarter from -$86.7 million in Q4 2025.
Kymera Therapeutics (KYMR) EBITDA (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of EBITDA data on file, last reported at -$75.2 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$75.2 million, down 17.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$319.1 million (down 33.44% YoY), and the FY2025 annual result was -$308.1 million, down 37.05% from the prior year.
- EBITDA rose to -$75.2 million in Q1 2026 per KYMR's latest filing, from -$86.7 million in the prior quarter.
- Over five years, EBITDA peaked at -$12.5 million in Q4 2023 and troughed at -$86.7 million in Q4 2025.
- A 5-year average of -$53.5 million and a median of -$49.8 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA jumped 63.22% in 2023, then tumbled 494.77% in 2024.
- A 5-year view of EBITDA shows it stood at -$33.9 million in 2022, then soared by 63.22% to -$12.5 million in 2023, then plunged by 494.77% to -$74.2 million in 2024, then decreased by 16.87% to -$86.7 million in 2025, then advanced by 13.21% to -$75.2 million in 2026.
- Business Quant data shows KYMR's EBITDA at -$75.2 million in Q1 2026, -$86.7 million in Q4 2025, and -$81.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -75.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.23 Mn |
| Dec 31, 2025 | -86.68 Mn |
| Sep 30, 2025 | -80.95 Mn |
| Jun 30, 2025 | -76.28 Mn |
| Mar 31, 2025 | -64.15 Mn |
| Dec 31, 2024 | -74.17 Mn |
| Sep 30, 2024 | -58.46 Mn |
| Jun 30, 2024 | -42.38 Mn |
| Mar 31, 2024 | -49.78 Mn |
| Dec 31, 2023 | -12.47 Mn |
| Sep 30, 2023 | -51.68 Mn |
| Jun 30, 2023 | -39.40 Mn |
| Mar 31, 2023 | -39.02 Mn |
| Dec 31, 2022 | -33.90 Mn |
| Sep 30, 2022 | -44.93 Mn |
| Jun 30, 2022 | -41.02 Mn |
| Mar 31, 2022 | -39.24 Mn |
| Dec 31, 2021 | -34.41 Mn |
| Sep 30, 2021 | -28.73 Mn |
| Jun 30, 2021 | -24.65 Mn |